200 related articles for article (PubMed ID: 35093921)
1. Efficacy and Safety of Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Living Donor Liver Transplantation: A Report of Two Cases.
Ichida A; Akamatsu N; Nagata R; Mihara Y; Kawaguchi Y; Bae SK; Ishizawa T; Kaneko J; Arita J; Hasegawa K
Anticancer Res; 2022 Feb; 42(2):1161-1167. PubMed ID: 35093921
[TBL] [Abstract][Full Text] [Related]
2. Efficient multiple treatments including molecular targeting agents in a case of recurrent hepatocellular carcinoma, post-living donor liver transplantation.
Suzuki R; Goto R; Kawamura N; Watanabe M; Ganchiku Y; Hatanaka KC; Hatanaka Y; Kamiyama T; Shimamura T; Taketomi A
Clin J Gastroenterol; 2022 Aug; 15(4):755-764. PubMed ID: 35635645
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.
Kim JM; Kwon CH; Joh JW; Choi MS; Lee JH; Koh KC; Paik SW; Kim GS; Kim SJ; Lee SK; Yoo BC
Transplant Proc; 2012 Mar; 44(2):403-8. PubMed ID: 22410028
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation.
Waghray A; Balci B; El-Gazzaz G; Kim R; Pelley R; Narayanan Menon KV; Estfan B; Romero-Marrero C; Aucejo F
Clin Transplant; 2013; 27(4):555-61. PubMed ID: 23758296
[TBL] [Abstract][Full Text] [Related]
5. Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
Tada T; Kumada T; Hiraoka A; Michitaka K; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Nakamura S; Nouso K; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y;
Oncology; 2021; 99(8):518-527. PubMed ID: 33906189
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.
Qiao ZY; Zhang ZJ; Lv ZC; Tong H; Xi ZF; Wu HX; Chen XS; Xia L; Feng H; Zhang JJ; Xia Q
Front Immunol; 2021; 12():653437. PubMed ID: 34349755
[TBL] [Abstract][Full Text] [Related]
7. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.
de'Angelis N; Landi F; Carra MC; Azoulay D
World J Gastroenterol; 2015 Oct; 21(39):11185-98. PubMed ID: 26494973
[TBL] [Abstract][Full Text] [Related]
8. Conversion Hepatectomy for Huge Hepatocellular Carcinoma With Arterioportal Shunt After Chemoembolization and Lenvatinib Therapy.
Sato N; Beppu T; Kinoshita K; Yuki H; Suyama K; Chiyonaga S; Motohara T; Komohara Y; Hara A; Akahoshi S
Anticancer Res; 2019 Oct; 39(10):5695-5701. PubMed ID: 31570469
[TBL] [Abstract][Full Text] [Related]
9. Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation.
Na GH; Hong TH; You YK; Kim DG
World J Gastroenterol; 2016 Jul; 22(25):5790-9. PubMed ID: 27433092
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan.
Shimozato N; Namisaki T; Okano A; Ohana M; Kinoshita D; Kawasaki T; Aihara Y; Nakatani T; Kinoshita H; Ann T; Saito KO; Yoshida M; Yoshiji H
Anticancer Res; 2022 Jan; 42(1):173-183. PubMed ID: 34969723
[TBL] [Abstract][Full Text] [Related]
12. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
Cho Y; Lee JH; Lee DH; Cho EJ; Yu SJ; Yi NJ; Lee KW; Kim YJ; Yoon JH; Suh KS
Oncotarget; 2017 Jul; 8(29):47555-47564. PubMed ID: 28548930
[TBL] [Abstract][Full Text] [Related]
13. Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma.
Kotani K; Enomoto M; Okada M; Yoshida K; Motoyama H; Fujii H; Hagihara A; Uchida-Kobayashi S; Morikawa H; Murakami Y; Tamori A; Kawada N
Clin J Gastroenterol; 2019 Aug; 12(4):355-360. PubMed ID: 31020569
[TBL] [Abstract][Full Text] [Related]
14. Lenvatinib as a therapy for unresectable hepatocellular carcinoma.
Spallanzani A; Orsi G; Andrikou K; Gelsomino F; Rimini M; Riggi L; Cascinu S
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1069-1076. PubMed ID: 30220234
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib use in the transplant setting.
Castelli G; Burra P; Giacomin A; Vitale A; Senzolo M; Cillo U; Farinati F
Liver Transpl; 2014 Sep; 20(9):1021-8. PubMed ID: 24809799
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
De Simone P; Crocetti L; Pezzati D; Bargellini I; Ghinolfi D; Carrai P; Leonardi G; Della Pina C; Cioni D; Pollina L; Campani D; Bartolozzi C; Lencioni R; Filipponi F
Transplant Proc; 2014; 46(1):241-4. PubMed ID: 24507059
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma.
Koizumi Y; Hirooka M; Hiraoka A; Ochi H; Tanaka T; Yukimoto A; Imai Y; Watanabe T; Yoshida O; Miyake T; Matsuura B; Michitaka K; Joko K; Abe M; Hiasa Y
Endocr J; 2019 Sep; 66(9):787-792. PubMed ID: 31142692
[TBL] [Abstract][Full Text] [Related]
18. Partial Splenic Embolization for Lenvatinib Therapy-associated Thrombocytopenia Among Patients With Hepatocellular Carcinoma.
Sato N; Beppu T; Kinoshita K; Yuki H; Suyama K; Yuruki H; Motohara T; Chiyonaga S; Akahoshi S
Anticancer Res; 2019 Dec; 39(12):6895-6901. PubMed ID: 31810959
[TBL] [Abstract][Full Text] [Related]
19. Time of hepatocellular carcinoma recurrence after liver resection and alpha-fetoprotein are important prognostic factors for salvage liver transplantation.
Lee S; Hyuck David Kwon C; Man Kim J; Joh JW; Woon Paik S; Kim BW; Wang HJ; Lee KW; Suh KS; Lee SK
Liver Transpl; 2014 Sep; 20(9):1057-63. PubMed ID: 24862741
[TBL] [Abstract][Full Text] [Related]
20. Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation.
Iavarone M; Invernizzi F; Czauderna C; Sanduzzi-Zamparelli M; Bhoori S; Amaddeo G; Manini MA; López MF; Anders M; Pinter M; Rodríguez MJB; Cristóbal MR; Soteras GA; Piñero F; Villadsen GE; Weinmann A; Crespo G; Mazzaferro V; Regnault H; Giorgio M; González-Diéguez ML; Donato MF; Varela M; Wörns MA; Bruix J; Lampertico P; Reig M
Am J Transplant; 2019 Nov; 19(11):3176-3184. PubMed ID: 31365177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]